
































	 In	 the	 present	 investigation,	 a	 series	 of	 1‐isonicotinoyl‐3‐methyl‐4‐(2‐(substituted‐
phenyl)hydrazono)‐1H‐pyrazol‐5(H)‐ones	 were	 synthesized	 by	 the	 reaction	 between
isonicotinohydrazide	 with	 substituted	 ethylacetoacetate	 derivatives	 using	 acetic	 acid	 as
solvent	 which	 yielded	 substituted	 pyrazol‐5(H)‐one	 derivatives.	 Newly	 synthesized
compounds	 were	 tested	 for	 their	 in	 vitro	 anti‐tubercular	 activity	 against	 Mycobacterium















In	 2009	 fell	 the	 126th	 anniversary	 of	 Robert	 Koch’s	
discovery	of	the	bacillus	Mycobacterium	tuberculosis	(MTB)	[1],	
the	 etiological	 agent	 of	 the	 well‐known	 respiratory	 disease	
Tuberculosis	 (TB).	 Despite	MTB	 being	 identified	more	 than	 a	
century	 ago	 and	 with	 many	 efficient	 drugs	 being	 discovered	
during	 that	 time	to	eradicate	 the	disease,	TB	still	 remains	one	
of	the	leading	causes	of	worldwide	illness	and	death.	Each	year,	
424,000	 people	 develop	 multiple	 drug‐resistant	 (MDR‐TB),	 a	
form	of	TB	that	does	not	respond	to	the	standard	treatment.	It	
emerges	 when	 there	 is	 mismanagement	 of	 drugs	 and	 under	
investment	in	quality	TB	control.	It	can	also	be	spread	from	one	
person	 to	 another	 [2].	 Moreover	 the	 emergence	 of	 multiple	
drug‐resistant	 strains	 and,	 more	 recently,	 extensively	 drug‐
resistant	 (XDR‐TB)	 strains	 makes	 the	 discovery	 and	 the	
development	of	new	drugs	a	priority	[3‐6].	Also,	the	emergence	
of	 AIDS,	 decline	 of	 socioeconomic	 standards	 and	 a	 reduced	
emphasis	 on	 tuberculosis	 control	 programs	 contribute	 to	 the	
disease’s	 resurgence	 in	 industrialized	 countries	 [7].	 Thus,	
Resistance	 of	 M.	 tuberculosis	 strains	 to	 anti‐mycobacterial	
agents	is	an	increasing	problem	worldwide	[8‐10].	
Isoniazid	 (INH),	 together	 with	 rifampicin	 and	
pyrazinamide,	 constitutes	 the	 backbone	 of	 a	 good	 outcome	 in	
the	 treatment	 of	 TB.	 INH	has	 a	 simple	 structure,	 containing	 a	
pyridine	 ring	 and	 a	 hydrazide	 group,	 and	 both	molecules	 are	
essential	 for	 its	 high	 activity	 against	M.	 tuberculosis	 [11‐14].	
Development	 of	 new	 drugs	 against	 TB	 derived	 from	 already	
known	molecules	 that	 have	been	 in	use	 for	 several	 years	 and	
have	 been	 proven	 safe	 and	 efficient	 is	 an	 attractive	 strategy	
from	an	economic,	pharmaceutical	and	clinical	viewpoint.	Since	
INH	is	a	very	important	drug	in	the	therapeutic	arsenal	for	TB	
treatment,	 efforts	 are	being	made	 toward	 the	development	 of	
new	 INH	 derivatives	 with	 greater	 activity,	 lower	 toxicity	 and	
fewer	 side	 effects	 [11,15‐23].	 Literature	 survey	 reveals	 that	
when	INH	molecule	incorporated	on	a	pyrazole	nucleus,	shows	
activity	 against	 strains	of	M.	 tuberculosis	 both	 susceptible	 and	
resistant	to	INH	[24,25].	Interestingly,	other	compounds	with	a	
halogen‐substituted	phenyl	group	showed	even	greater	activity	
[26].	We	believe	 that	 the	 INH	moiety	 is	not	 the	only	structure	
responsible	 for	 the	 anti‐mycobacterial	 activity	 because	
pyrazoles	 with	 different	 substituents	 exhibited	 very	 different	
activities	 [27‐30].	 Therefore,	 it	 is	 possible	 that	 attaching	
chemical	groups	that	aid	the	penetration	of	INH	would	make	M.	
tuberculosis	strains	more	susceptible	to	this	drug	[27,29].	
The	 current	 work	 describes	 the	 synthesis	 of	 the	 novel	









by	open	 tube	 capillary	method	and	 are	uncorrected.	Purity	 of	
the	 compounds	 was	 checked	 on	 thin	 layer	 chromatography	









spectrometer	 using	 TMS	 as	 internal	 standard	 in	 DMSO‐
d6/CDCl3,	respectively.	Mass	spectra	were	recorded	on	a	Bruker	











2‐oxobutanolate	 derivatives	 were	 obtained	 by	 reacting	
ethyl	acetoacetate	 (0.01	mol)	with	appropriate	diazonium	salt	





The	 solution	 of	 appropriate	 2‐oxobutanolate	 derivative	
(0.01	mol)	and	isonicotinohydrazide	(0.01	mol)	in	ethanol	(15	




dried	 and	 recrystallized	 from	 ethanol	 to	 give	 the	 desired	
pyrazolones	(5a‐r).	
1‐isonicotinoyl‐3‐methyl‐4‐(2‐phenylhydrazono)‐1H‐pyrazol‐




128.71,	 148.11,	 162.11	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	 117.90‐
143.07	 (Ar‐C).	 MS	 (EI,	 	 m/z):	 307	 (M+).	 Anal.	 Calcd.	 for	






aromatic),	 11.50	 (1H,	 s,	 NH).	 13C	 NMR	 (100	MHz,	 DMSO‐d6,	 δ	
ppm):		12.11	(CH3),	21.77	(Ar‐CH3),	127.14,	147.22,	163.72	(Ar‐
C	 of	 pyrazol‐(5H)‐one),	 122.50‐151.11	 (Ar‐C).	 MS	 (EI,	 m/z):	















aromatic),	 11.50	 (1H,	 s,	 NH).	 13C	 NMR	 (100	MHz,	 DMSO‐d6,	 δ	
ppm):	12.1	1(CH3),	21.99	(Ar‐CH3),	127.75,	148.26,	163.17	(Ar‐
C	 of	 pyrazol‐(5H)‐one),	 116.90‐150.10	 (Ar‐C).	 MS	 (EI,	 m/z):		
321	 (M+).	 Anal.	 Calcd.	 for	 C17H15N5O2	 (321.33):	 C,	 63.54;	 H,	
4.71;	N,	21.79.	Found:	C,	63.44;	H,	4.77;	N,	21.91%.	
1‐isonicotinoyl‐3‐methyl‐4‐(2‐(2‐nitrophenyl)hydrazono)‐
1H‐pyrazol‐5(4H)‐one	 (5e):	 FT‐IR	 (ν,	 cm‐1):	 3200‐3190	 (NH),	
1680	 (C=O),	 1582	 (C=N),	 3270	 (C‐H),	 2928	 (CH3),	 1344	 and	
1560	(NO2).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.15	(3H,	s,	
CH3),	 7.40‐8.89	 (8H,	m,	 aromatic),	 11.61	 (1H,	 s,	NH).	 13C	NMR	
(100	 MHz,	 DMSO‐d6,	 δ	 ppm):	 11.13	 (CH3),	 128.72,	 148.23,	
162.14	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	 127.10‐149.70	 (Ar‐C).	 MS	
(EI,	 m/z):	 	 352	 (M+).	 Anal.	 Calcd.	 for	 C16H12N6O4	 (352.30):	 C,	
54.55;	H,	3.43;	N,	23.85.	Found:	C,	54.11;	H,	3.63;	N,	23.73%.	
1‐isonicotinoyl‐3‐methyl‐4‐(2‐(3‐nitrophenyl)hydrazono)‐
1H‐pyrazol‐5(4H)‐one	 (5f):	 FT‐IR	 (ν,	 cm‐1):	 3200‐3190	 (NH),	
1680	 (C=O),	 1582	 (C=N),	 3270	 (C‐H),	 2928	 (CH3),	 1344	 and	
1560	(NO2).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.10	(3H,	s,		
CH3),	 7.40‐8.89	 (8H,	m,	 aromatic),	 11.63	 (1H,	 s,	NH).	 13C	NMR	
(100	 MHz,	 DMSO‐d6,	 δ	 ppm):	 11.18	 (CH3),	 129.81,	 149.32,	
163.21	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	 107.11‐148.92	 (Ar‐C).	 MS	
(EI,	 m/z):	 	 352	 (M+).	 Anal.	 Calcd.	 for	 C16H12N6O4	 (352.30):	 C,	
54.55;	H,	3.43;	N,	23.85.	Found:	C,	54.22;	H,	3.34;	N,	23.77%.	
1‐isonicotinoyl‐3‐methyl‐4‐(2‐(4‐nitrophenyl)hydrazono)‐
1H‐pyrazol‐5(4H)‐one	 (5g):	 FT‐IR	 (ν,	 cm‐1):	 3200‐3190	 (NH),	
1680	 (C=O),	 1582	 (C=N),	 3270	 (C‐H),	 2928	 (CH3),	 1344	 and	
1560	(NO2).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.10	(3H,	s,		
CH3),	 7.20‐8.80	 (8H,	m,	 aromatic),	 11.62	 (1H,	 s,	NH).	 13C	NMR	
(100	 MHz,	 DMSO‐d6,	 δ	 ppm):	 11.20	 (CH3),	 129.71,	 149.12,	
163.03	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	 117.21‐147.89	 (Ar‐C).	 MS	
(EI,	 m/z):	 	 352	 (M+).	 Anal.	 Calcd.	 for	 C16H12N6O4	 (352.30):	 C,	
54.55;	H,	3.43;	N,	23.85.	Found:	C,	54.42;	H,	3.33;	N,	23.63%.		
4‐(2‐(2‐chlorophenyl)hydrazono)‐1‐isonicotinoyl‐3‐methyl‐




d6,	 δ	 ppm):	 11.39	 (CH3),	 128.71,	 148.12,	 162.01	 (Ar‐C	 of	








d6,	 δ	 ppm):	 11.92	 (CH3),	 128.18,	 148.21,	 162.10	 (Ar‐C	 of	












Calcd.	 for	 C16H12N5O2Cl	 (341.75):	 C,	 56.23;	 H,	 3.54;	 N,	 20.49.	
Found:	C,	56.21;	H,	3.69;	N,	20.77%.	
4‐(2‐(2,4‐dichlorophenyl)hydrazono)‐1‐isonicotinoyl‐3‐
methyl‐1H‐pyrazol‐5(4H)‐one	 (5k):	FT‐IR	 (ν,	 cm‐1):	 3203‐3187	
(NH),	1680	(C=O),	1586	(C=N),	3270	(C‐H),	2928	(CH3),	782	(C‐
Cl).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	 ppm):	 2.30	 (3H,	 s,	 	 CH3),	
7.55‐7.90	 (7H,	m,	 aromatic),	 11.09	 (1H,	 s,	NH).	 13C	NMR	 (100	





methyl‐1H‐pyrazol‐5(4H)‐one	 (5l):	 FT‐IR	 (ν,	 cm‐1):	 3203‐3187	
(NH),	1680	(C=O),	1586	(C=N),	3270	(C‐H),	2928	(CH3),	782	(C‐
Cl).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	 ppm):	 2.33	 (3H,	 s,	 	 CH3),	
6.77‐7.90	 (7H,	m,	 aromatic),	 11.09	 (1H,	 s,	NH).	 13C	NMR	 (100	







Cl).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	 ppm):	 2.31	 (3H,	 s,	 	 CH3),	
7.02‐7.90	 (7H,	m,	 aromatic),	 13.18	 (1H,	 s,	NH).	 13C	NMR	 (100	





methyl‐1H‐pyrazol‐5(4H)‐one	 (5n):	FT‐IR	 (ν,	 cm‐1):	 3206‐3190	
(NH),	1689	 (C=O),	1586	 (C=N),	3270	 (C‐H),	 2928	 (CH3),	 2830	
(OCH3).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.15	(3H,	s,		CH3),	
3.92	 (3H,	 s,	 	OCH3),	 6.85‐8.10	 (8H,	m,	 aromatic),	 11.18	 (1H,	 s,	
NH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ	ppm):	12.18	(CH3),	58.69	
(OCH3)	 129.96,	 147.02,	 163.00	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	
128.97‐148.96	(Ar‐C).	MS	(EI,	m/z):		338	(M+).	Anal.	Calcd.	for	
C17H15N5O3	 (337.12):	 C,	 60.53;	 H,	 4.48;	 N,	 20.76.	 Found:	 C,	
60.62;	H,	4.39;	N,	20.72%.	
1‐isonicotinoyl‐4‐(2‐(3‐methoxyphenyl)hydrazono)‐3‐
methyl‐1H‐pyrazol‐5(4H)‐one	 (5o):	FT‐IR	 (ν,	 cm‐1):	 3206‐3190	
(NH),	1689	 (C=O),	1586	 (C=N),	3270	 (C‐H),	 2928	 (CH3),	 2830	
(OCH3).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.17	(3H,	s,		CH3),	
3.89	 (3H,	 s,	 	OCH3),	 6.27‐7.89	 (8H,	m,	 aromatic),	 12.11	 (1H,	 s,	
NH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ	ppm):	12.18	(CH3),	59.97	
(OCH3)	 129.96,	 147.11,	 163.19	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	
129.91‐149.89	(Ar‐C).	MS	(EI,	m/z):		338	(M+).	Anal.	Calcd.	for	
C17H15N5O3	 (337.12):	 C,	 60.53;	 H,	 4.48;	 N,	 20.76.	 Found:	 C,	
60.74;	H,	4.50;	N,	20.74%.	
1‐isonicotinoyl‐4‐(2‐(4‐methoxyphenyl)hydrazono)‐3‐
methyl‐1H‐pyrazol‐5(4H)‐one	 (5p):	FT‐IR	 (ν,	 cm‐1):	 3206‐3190	
(NH),	1689	 (C=O),	1586	 (C=N),	3270	 (C‐H),	 2928	 (CH3),	 2830	
(OCH3).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.11	(3H,	s,		CH3),	
3.89	 (3H,	 s,	 	OCH3),	 7.02‐7.89	 (8H,	m,	 aromatic),	 12.15	 (1H,	 s,	
NH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ	ppm):	12.18	(CH3),	59.22	
(OCH3)	 129.98,	 147.02,	 163.00	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	
128.19‐147.97	(Ar‐C).	MS	(EI,	m/z):		338	(M+).	Anal.	Calcd.	for	
C17H15N5O3	 (337.12):	 C,	 60.53;	 H,	 4.48;	 N,	 20.76.	 Found:	 C,	
60.65;	H,	4.48;	N,	20.78%.	
4‐(2‐(2,4‐dimethoxyphenyl)hydrazono)‐1‐isonicotinoyl‐3‐
methyl‐1H‐pyrazol‐5(4H)‐one	 (5q):	FT‐IR	 (ν,	 cm‐1):	 3210‐3190	
(NH),	1690	 (C=O),	1586	 (C=N),	3270	 (C‐H),	 2928	 (CH3),	 2830	
(OCH3).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	2.10	(3H,	s,		CH3),	
3.50	 (3H,	 s,	 	 CH3),	 3.89	 (3H,	 s,	 	 OCH3),	 6.77‐8.81	 (7H,	 m,	
aromatic),	 11.11	 (1H,	 s,	 NH).	 13C	 NMR	 (100	MHz,	 DMSO‐d6,	 δ	
ppm):	 12.20	 (CH3),	 57.71	 	 (2xOCH3),	 129.89,	 147.11,	 164.11	
(Ar‐C	of	pyrazol‐(5H)‐one),	121.19‐149.77	(Ar‐C).	MS	(EI,	m/z):		
368	 (M+).	 Anal.	 Calcd.	 for	 C18H17N5O4	 (367.36):	 C,	 58.85,	 H,	
4.66;	N,	19.06.	Found:	C,	58.95;	H,	4.78;	N,	19.18%.	
4‐(2‐(1‐isonicotinoyl‐3‐methyl‐5‐oxo‐1H‐pyrazol‐4(5H)‐
ylidene)hydrazinyl)benzene‐sulfonamide	 (5r):	 FT‐IR	 (ν,	 cm‐1):	
3206‐3190	 (NH),	 1689	 (C=O),	 1586	 (C=N),	 327	 0(C‐H),	 2928	
(CH3),	1339‐1337,	1147‐1137	(SO2),	3440	(NH2).	1H	NMR	(400	
MHz,	 DMSO‐d6,	 δ	 ppm):	 2.15	 (3H,	 s,	 	 CH3),	 6.91‐7.89	 (8H,	 m,	
aromatic),	 13.11	 (1H,	 s,	 NH),	 8.83	 (2H,	 s,	 SO2NH2).	 13C	 NMR	
(100	 MHz,	 DMSO‐d6,	 δ	 ppm):	 12.29	 (CH3),	 127.77,	 147.21,	
165.09	 (Ar‐C	 of	 pyrazol‐(5H)‐one),	 129.30‐148.19	 (Ar‐C).	 MS	






6.25	 µg/mL	 (or	molar	 equivalent	 of	 highest	molecular	weight	
compound	 in	 a	 series	 of	 congeners)	 against	 M.	 tuberculosis	
H37Rv	 (ATCC27294)	 in	 BACTEC	 12B	 medium	 using	 the	
BACTEC	 460	 radiometric	 system	 [32,33].	 Compounds	
demonstrating	 at	 least	 90%	 inhibition	 in	 the	 primary	 screen	
were	re‐examined	at	lower	concentration	(MIC)	in	broth	micro‐
dilution	 assay	with	 Alamar	 Blue.	 The	MIC	was	 defined	 as	 the	
lowest	 concentration	 inhibiting	 99%	 of	 the	 inoculum.	
Concurrent	with	 the	 determination	 of	MICs,	 compounds	were	
tested	for	cytotoxicity	(IC50)	in	VERO	at	concentration	equal	to	
and	greater	than	the	MIC	for	M.	tuberculosis	H37Rv	after	72	h	of	












2‐oxobutanolate	 (3a‐r)	 were	 prepared	 by	 reacting	
ethylacetoacetate	with	appropriate	diazonium	salt	of	aromatic	
amines	in	the	presence	of	ethanol.	Reaction	between	this	newly	
synthesized	 2‐oxobutanolate	 derivatives	 and	 isonicotino	





the	 synthesized	 compounds	 were	 in	 full	 agreement	 with	 the	
proposed	 structures.	 Final	 compounds	 in	 general,	 in	 the	
infrared	 spectra	 (IR),	 revealed	 NH,	 C=O,	 C=N,	 C‐N,	 and	 CH3	
peaks	at	3220,	1680,	1590,	1320,	2928	cm‐1,	respectively.	
In	 the	 nuclear	 magnetic	 resonance	 spectra	 (1H	 and	 13C	
NMR)	 the	 signals	 of	 the	 respective	 protons	 of	 the	 prepared	
compounds	were	verified	on	the	basis	of	 their	chemical	shifts,	
multiplicities	 and	 coupling	 constants.	 The	 spectra	 showed	 1H	
NMR	singlet	at	δ	range	2.10‐2.33	ppm	corresponding	to	methyl	
group;	 multiplet	 at,	 δ	 range	 6.50‐8.80	 ppm	 for	 aromatic	
protons;	 singlet	 at	 δ	 range	 11.09‐13.18	 ppm	 for	 NH	 proton.	
Similarly,	13C	NMR	signals	at	δ	range	11.18‐12.91	ppm	(C14	of	
CH3),	127.14‐129.96	ppm	(C13),	147.02‐149.32	ppm	(C12)	and	
162.11‐165.09	 ppm	 (C11)	 of	 pyrazolone	 ring	 and	 signals	 at	δ	
range	 107.11‐151.11	 ppm	 of	 aromatic	 carbons,	 respectively.	





Among	 the	 ring	 substituted	 pyrazolone	 derivatives	 (5a‐r)	
were	tested	for	their	anti‐mycobacterial	activity	in	vitro	against	









Compound	 R	 Yield	(%)	 Melting	Point	(C)	 Mol.	Formula	 Mol.	wt.	(g)	 UV,	max	(CH3OH)	(nm)	
5a	 H	 80	 198‐200 C16H13N5O2 307.31 238.4	
5b	 2‐CH3	 70	 240‐241 C17H15N5O2 321.33 369.3	
5c	 3‐CH3	 60	 170‐173 C17H15N5O2 321.33 373.7	
5d	 4‐CH3	 65	 105‐107 C17H15N5O2 321.33 379.9	
5e	 2‐NO2	 75	 185‐186 C16H12N6O4 352.30 367.6	
5f	 3‐NO2	 68	 250‐252 C16H12N6O4 352.30 384.8	
5g	 4‐NO2	 78	 210‐212 C16H12N6O4 352.30 389.9	
5h	 2‐Cl	 72	 130‐132 C16H12ClN5O2 341.75 363.2	
5i	 3‐Cl	 79	 125‐126 C16H12ClN5O2 341.75 377.6	
5j	 4‐Cl	 75	 190‐192 C16H12ClN5O2 341.75 378.8	
5k	 2,4‐Cl2	 77	 187‐189 C16H11C	l2N5O2 376.20 376.7	
5l	 2,5‐Cl2	 79	 189‐191 C16H11C	l2N5O2 376.20 375.2	
5m	 2,6‐Cl2	 82	 192‐194 C16H11Cl2N5O2 376.20 376.9	
5n	 2‐OCH3	 72	 144‐147 C17H15N5O3 337.33 355.9	
5o	 3‐OCH3	 58	 149‐150 C17H15N5O3 337.33 359.7	
5p	 4‐OCH3	 69	 152‐154 C17H15N5O3 337.33 357.8	
5q	 2,4‐OCH3	 72	 167‐169 C18H17N5O4 367.36 483.4	
5r	 4‐SO2NH2	 77	 177‐179 C16H14N6O4S 386.89 478.4	
	
	












5a	 >6.25	 64 0.0354	 ‐
5b	 >6.25	 12 0.1140	 6.25
5c	 >6.25	 32 0.1706	 ‐
5d	 >6.25	 28 0.1135	 6.25
5e	 >6.25	 44 0.0167	 ‐
5f	 >6.25	 14 0.0132	 6.25
5g	 >6.25	 26 0.0142	 6.25
5h	 >6.25	 63 0.0130	 6.25
5i	 6.25	 62 0.0138	 6.25
5j	 >6.25	 64 0.0133	 6.25
5k	 >6.25	 69 0.0118	 5.67
5l	 6.25	 96 0.0084	 5.77
5m	 6.25	 98 0.0034	 1.66
5n	 >6.25	 94 0.0092	 4.12
5o	 >6.25	 88 0.0108	 6.25
5p	 >6.25	 86 0.0103	 6.25
5q	 >6.25	 89 0.0107	 6.25




used	 for	 comparison.	 Among	 the	 18	 newly	 synthesized	
compounds,	5l,	5m,	5n	 and	5r	 produced	 highest	 efficacy	 and	
exhibited	>90%	inhibition	at	a	concentration	of	0.0084,	0.0034,	
0.0092	 and	 0.0032	 µM	 followed	 by	 5o,	 5p	 and	 5q	 which	
showed	moderate	 to	 good	 inhibitory	 activity	with	0.0108	µM,	
0.0103	µM	and	0.0107	µM,	respectively.	Thus,	the	2,6‐dichloro	
and	 4‐SO2NH2	 groups	 substitution	 derivatives	 displayed	
relatively	 higher	 inhibitory	 activity	 in	 general.	 However,	 the	
electron	rich	groups	such	as,	2,5‐chloro,	2‐methoxy,	3‐methoxy,	
4‐methoxy,	 and	 2,4‐dimethoxy	 substituted	 analogue	
compounds	produced	significant	increase	in	inhibitory	activity	
against	M.	 tuberculosis	H37Rv.	 On	 the	 other	 hand,	 pyrazolone	
analogues	 with	 methyl	 group	 substitution	 5b,	 5c,	 5d	 and	




All	 the	 newly	 synthesized	 compounds	 (5a‐r)	 were	 tested	
for	 cytotoxicity	 (IC50)	 in	VERO	cells	 at	 concentrations	of	62.5	
µg/mL.	 After	 72	 h	 of	 exposure,	 viability	 was	 assessed	 on	 the	
basis	 of	 cellular	 conversion	 of	 MTT	 into	 a	 formazan	 product	
using	 the	 Promega	 Cell	 Titer	 96	 Non‐radioactive	 Cell	







Among	 the	 newer	 derivatives,	 it	 is	 conceivable	 that	
derivatives	showing	anti‐mycobacterial	activity	can	be	 further	
modified	to	exhibit	better	potency	than	the	standard	drugs.	The	
pyrazolone	 derivatives	 discovered	 in	 this	 study	 may	 provide	
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